Appeal type: Medical necessity
Decision: Overturned

Diagnosis: Ulcerative Colitis
Treatment: Stelara 90MG/ML SC SOSY, Dosed Every Six Weeks

The insurer denied the Stelara 90MG/ML SC SOSY, Dosed Every Six Weeks.
The denial is overturned.

The patient is a female with moderate to severe ulcerative colitis. She has failed six-mercaptopurine (6-MP), Humira, Entyvio, Remicade and Xeljanz. The patient started Stelara 90 milligrams every eight weeks, and had some, but not a complete response, with breakthrough symptoms. The attending phycisian (AP) is requesting to increase Stelara to 90 milligrams every six weeks. Stelara was denied, as the dose is higher than the Food and Drug Administration (FDA) approved dose.

Yes, the proposed Stelara 90MG/ML SC SOSY, Dosed Every Six Weeks, is medically necessary.
Medical literature supports dose intensification of biologics in patients who lose response to Food and Drug Administration (FDA) approved dosing. Stelara has been found to be safe and effective at doses as high as 90 milligrams every four weeks. 

Results from a retrospective cohort study of patients with Crohn's disease (CD) reported that among 122 patients on ustekinumab, 21 (17% [percent]) patients on every eight week maintenance dosing required dose intensification (frequency increased to every four weeks, every six weeks, or a combination of intravenous (IV) booster and frequency increase to every six weeks or every four weeks). A total of 11 patients (52%) had clinical response after dose escalation (two [18%] were primary nonresponders to induction while nine [82%] had poor initial clinical response). 

A multicenter, retrospective, open-label cohort study of adults with moderate to severe Crohn's disease (CD) was conducted to evaluate the long-term maintenance efficacy of ustekinumab therapy. During the maintenance therapy, dose escalation was required in 16.3% (17/104) patients and a combination strategy of reinduction and dose escalation was required in 6.7% (7/104) of patients. The most common escalated maintenance dosing was 90 milligrams subcutaneous every four or six weeks. Clinical response was regained in 52.9% (9/17) of patients who had dose escalation, and 57.1% (4/7) of patients who had combined reinduction and dose escalation. 

Results from a retrospective, multicenter, open-label study of patients with refractory Crohn's disease (CD) receiving ustekinumab, demonstrated that, among 11 patients who required a dosing interval reduction (includes 90 milligrams subcutaneous every eight weeks to every four weeks, 90 milligrams subcutaneous every eight weeks to every six weeks), clinical improvement was seen in 73% (8/11) of patients. 

Results from a retrospective, open-label, observational study of ustekinumab for the treatment of anti-tumor necrosis factor (anti-TNF) resistant CD patients, demonstrated that, among patients who achieved clinical response at the last followup, dose escalation was required in 35% (7/20) of patients who received ustekinumab 90 milligrams subcutaneous every eight weeks. 

While the studies were all done in patients with Crohn's disease, as Stelara is Food and Drug Admionistrtaion (FDA) approved for use in ulcerative colitis, the premise is the same, and such dose intensification of Stelara in ulcerative colitis is widely used and accepted by gastroenterologists. Therefore, as dose intensification of Stelara in patients with irritable bowel syndrome (IBD) has been found to be safe and effective at doses as high as 90 milligrams every four weeks, the requested Stelara 90 milligrams every six weeks is clinically appropriate, accepted standard of care and is medically necessary.

No, as the proposed treatment is medically necessary, the health plan act did not act reasonably, with sound medical judgment and in the best interest of the patient by denying it.